Deals worth $370bn torpedoed by Obama administration
More mergers and acquisitions torpedoed than during Clinton and Bush eras together
The Obama administration has blocked several big telecoms deals in a bid to protect competition. Photograph: Kevin Lamarque/Reuters
US companies have abandoned $370 billion of large deals since President Barack Obama came into power in 2009, after regulators in his administration blocked an unprecedented number of transactions to protect competition, jobs and the US tax base.
Corporate America responded with dismay on Tuesday after the US Treasury proposed new rules that torpedoed Pfizer’s takeover of Dublin-based Allergan, worth $160 billion or $190 billion including debt, in an attempt to stop the drugmaker moving its headquarters to Ireland so it could avoid billions of dollars in US taxes.
It was the latest in a series of interventions by branches of the Obama administration, which has thwarted more big-ticket mergers and acquisitions than were blocked during the Clinton and Bush eras put together, according to an FT analysis of abandoned deals worth more than $10 billion.
In 2014, AbbVie pulled the plug on its $55 billion takeover of Ireland-based Shire following a similar putative rule change by the US Treasury.
Widespread oppositionTime Warner Cable
AT&T dropped its $39 billion bid for T-Mobile US in 2011 after the DoJ sued to block the deal, while Nasdaq’s $11 billion attempt to take over the New York Stock Exchange was thwarted by antitrust concerns.
In contrast, the George W Bush administration blocked just one large deal – the $27 billion takeover of Hughes Electronic by EchoStar, the satellite TV group.
Two big M&A transactions were torpedoed under Bill Clinton: the $12 billion takeover of military supplier Northrop Grumman by its rival Lockheed Martin, and MCI WorldCom’s $125 billion bid for Sprint, the mobile phone network.
The interventionist posture has provoked anger on Wall Street. One large life sciences investor with holdings in Pfizer, Allergan and AbbVie said the administration was building an “artificial prison for pharmaceutical companies, rather than dealing with the underlying issue” of relatively high taxes for US companies.
An investment banker said the deal highlighted how the White House had succumbed to a “leftist rhetoric” that had its roots in the aftermath of the financial crisis.
Debbie Feinstein, director of the Federal Trade Commission’s competition bureau, told the Financial Times: “There’s no question that we’re going to be aggressive against conduct or mergers that are going to harm competition or consumers. That’s our job and we take it very seriously and we’re going to do it very carefully. We’re not afraid to litigate.”
– (Copyright The Financial Times Limited 2016)